1	Can individuals with suboptimal antibody responses to conventional
2	antiviral vaccines acquire adequate antibodies from SARS-CoV-2 mRNA
3	vaccination?
4	
5	Wataru Ogura <sup>1</sup> , Kouki Ohtsuka <sup>2*</sup> , Sachiko Matsuura <sup>1</sup> , Takahiro Okuyama <sup>1</sup> , Satsuki
6	Matsushima <sup>2</sup> , Satoko Ymasaki <sup>2</sup> , Hiroyuki Miyagi <sup>1</sup> , Kumiko Sekiguchi <sup>1</sup> , Hiroaki
7	Ohnishi <sup>2</sup> , Takashi Watanabe <sup>2</sup>
8	
9	<sup>1</sup> Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo, Japan
10	<sup>2</sup> Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka,
11	Tokyo, Japan
12	
13	* Corresponding author
14	E-mail: kouki7@ks.kyorin-u.ac.jp
15	
16	Funding Statement
17	This study did not receive any funding
18	
19	Reprint billing address
20	Kouki Ohtsuka
21	Department of Laboratory Medicine

- 22 Kyorin University School of Medicine
- 23 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan
- 24 E-mail: kouki7@ks.kyorin-u.ac.jp

## 25 Abstract:

### 26 **Objective**

27	In Japan, healthcare workers (HCWs) are vaccinated against contagious viruses
28	(measles, rubella, chickenpox, mumps, and hepatitis B) to prevent nosocomial infection;
29	however, some do not produce sufficient antibodies (suboptimal responders). Whether
30	suboptimal responders to live attenuated viruses or inactivated viruses vaccines can
31	produce adequate antibodies to severe acute respiratory syndrome coronavirus 2
32	(SARS-CoV-2) mRNA vaccines remains to be elucidated.
33	Methods
34	In this prospective cohort study, SARS-CoV-2 anti-spike antibodies were
35	measured 11 times, from before the first BNT162b2 vaccination to 5 months after the
36	second vaccination. Antibody titers of suboptimal and normal responders were
37	compared. SARS-CoV-2 neutralizing antibody activity was measured twice in
38	suboptimal responders, 1 week to 1 month, and 5 months after the second vaccination.
39	Patients
40	This study included 50 HCWs who received two doses of mRNA BNT162b2
41	vaccine 3 weeks apart.
42	Results
43	After vaccination, the SARS-CoV-2 anti-spike antibody was detectable in the
44	samples from suboptimal and normal responders at each timepoint. The median SARS-
45	CoV-2 anti-spike antibody titer was higher in suboptimal responders than in normal
46	responders 1 week after receiving the second dose of BNT162b2 vaccine (3721.0 vs.
47	2251.5, P=0.029). Suboptimal responders had SARS-CoV-2 neutralizing antibody

- 48 activity 1 week to 1 month, and 5 months after the second vaccination, which exceeded
- 49 the positive threshold 5 months after the second vaccination.
- 50 Conclusion
- 51 After BNT162b2 vaccination, suboptimal responders acquired adequate SARS-
- 52 CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies to prevent SARS-CoV-2.
- 53 These results suggest that vaccination with mRNA vaccine against SARS-CoV-2 should
- also be recommended for suboptimal responders to conventional vaccines.
- 55
- 56 Keywords:
- 57 coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2
- 58 (SARS-CoV-2), mRNA vaccine, anti-spike antibody, neutralizing antibody

# 60 Introduction

61	Coronavirus disease (COVID-19), which is caused by severe acute respiratory
62	syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic (1-4). In view of
63	the high number of cases of severe illness and death due to COVID-19, vaccination
64	against SARS-CoV-2 infection is crucial.
65	SARS-CoV-2 has an enveloped, single, positive-stranded RNA genome that
66	encodes four major viral structural proteins, namely, the nucleocapsid, spike, envelope,
67	and membrane proteins; the latter three proteins are found in its membrane. The spike
68	protein guides viral entry into host cells by binding to angiotensin-converting enzyme 2
69	(ACE2) receptors, which are widely expressed on epithelial cells and macrophages (5-7)
70	and is thus an ideal target for messenger RNA (mRNA) vaccine development.
71	The BNT162b2 mRNA vaccine (Pfizer-BioNTech) is highly effective at
72	preventing clinically significant COVID-19 (8-10), reducing the incidence of
73	asymptomatic infection and associated infectivity (11,12), and preventing the spread of
74	COVID-19 (9). The BNT162b2 vaccine was the first SARS-CoV-2 vaccine to be
75	approved in Japan, and priority vaccination of healthcare workers (HCWs) began in
76	February 2021 in order to safeguard the medical delivery system (13).
77	HCWs also have a high risk of infection with other contagious viruses such as
78	measles, rubella, chickenpox, mumps, and hepatitis B. Therefore, in Japan, HCWs are
79	vaccinated against these viruses to prevent nosocomial infections and viral antibody
80	titers are measured to ensure the presence of protective antibody levels (14). However,
81	some individuals do not develop adequate antibody titers against contagious viruses
82	even after vaccination. Such individuals are called suboptimal responders. It is unclear

83	whether suboptimal responders to conventional vaccines can produce adequate SARS-
84	CoV-2 antibodies, including neutralizing antibodies, after vaccination with the
85	BNT162b2 vaccine to protect them against SARS-CoV-2 infection. Therefore, in this
86	study, we investigated whether suboptimal responders acquired SARS-CoV-2 anti-spike
87	and SARS-CoV-2 neutralizing antibodies after vaccination with the BNT162b2 vaccine.
88	

- 89 Materials and methods
- 90

### 91 **Participants**

92 The study was conducted at Kyorin University Hospital in Tokyo, Japan.
93 HCWs at the hospital received two doses of the BNT162b2 vaccine 3 weeks apart. The
94 participants were HCWs at the hospital who agreed to participate in the study and to
95 periodically donate blood samples before and after vaccination. Those whose antibody
96 levels were below the standard values for preventing infection after receiving two or
97 more doses of vaccine against measles, rubella, chickenpox, mumps, or hepatitis B
98 viruses were classified as suboptimal responders.

99

### 100 SARS-CoV-2 anti-spike antibody assay

SARS-CoV-2 anti-spike antibody measurements were performed on serum
obtained from centrifuged peripheral blood using the Elecsys Anti-SARS-CoV-2 S RUO
(Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on a Cobas 6000 (Roche
Diagnostics) analyzer via the double-antigen sandwich enzyme-linked immunoassay
method (15). Samples were collected before the first dose of BNT162b2 vaccine was

administered; 3 days after the first vaccination; 1, 2, and 3 weeks after the first

107 vaccination; 1 week after the second vaccination; and 1, 2, 3, 4, and 5 months after the

second vaccination. The measurement range of the antibody assay was 0.4–250, and

samples with an antibody titer of  $\geq 250$  U/mL were assayed again after dilution.

110

### 111 SARS-CoV-2 neutralizing antibody assay

112 Using serum obtained from the peripheral blood of suboptimal responders after

113 vaccination, SARS-CoV-2 neutralizing antibody activity was measured at Osaka

114 University Microbial Disease Research Association Laboratory. A 50% inhibitory

dilution factor (ID<sub>50</sub>) using pseudovirus (16) was measured, and ID<sub>50</sub> values of  $\geq$ 50 was

116 considered positive (17). For the neutralization assay,  $60 \mu$ L of pseudovirus, which is

117 equivalent to  $2.5 \times 10^6$  relative light units (RLU)/mL, was incubated with 60  $\mu$ L of serial

dilutions of serum samples for 1 h at  $37\Box$ . After incubation, 100 µL of the mixture was

added to the Vero cells in a 96-well plate. The cells were lysed 24 h post-infection,

120 luciferase was activated using the Luciferase Assay System (E1501, Promega,

121 Wisconsin, USA), and RLU were measured using a Synergy LX analyzer (BioTek,

122 USA). Percent neutralization was calculated using GraphPad Prism 8.0.2 (GraphPad

123 Software, San Diego, California, USA). Percentages of RLU reduction (inhibition rate)

124 were calculated as follows: 1 – (RLU of sample sera – pseudovirus only wells) / (RLU

from medium only wells – pseudovirus only wells)  $\times$  100%. The titers of neutralizing

sera were calculated as ID<sub>50</sub>. The transition of neutralizing antibody activity values after

127 vaccination in suboptimal responders was examined 1 week to 1 month and 5 months

128 after receiving the second dose of the BNT162b2 vaccine.

129

### 130 Statistical analysis

131 Nonparametric continuous data are reported as median and interguartile range 132 (IQR). The Mann–Whitney U test was performed to assess whether differences between 133 cohorts were statistically significant. Two-sided *P*-values of <0.05 were considered 134 statistically significant. The Wilcoxon matched-pairs signed rank test was performed to 135 assess whether differences in antibody levels within an individual at different time 136 points were statistically significant. To compare the age (ratio of the number of 137 individuals aged 20–40 years and those aged 50–60 years) and sex compositions of the 138 suboptimal responders and normal responders, Fisher's exact test was performed to test 139 the statistical significance. The Mann-Whitney U test was performed to test for 140 statistically significant differences in antibody levels between suboptimal responders 141 and normal responders 1 week after the second vaccination. All statistical analyses were 142 performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, 143 Japan), which is a graphical user interface for R (The R Foundation for Statistical 144 Computing, Vienna, Austria) (18). Specifically, EZR is a modified version of R 145 commander (version 1.54) that has been designed to add statistical functions frequently 146 used in biostatistics.

147

### 148 **Results**

The suboptimal responders comprised three men (L1, L2, L4) with negative
(titer <16.0) anti-measles immunoglobulin G (IgG) antibody titer after measles virus</li>
vaccination and one woman (L3) with a negative (titer <4.0) anti-mumps IgG antibody</li>

152	titer after mumps virus vaccination. Forty-six participants, comprising 12 men and 34
153	women, had antiviral antibody titers after vaccination against other viruses above the
154	standard value (normal responders). The four suboptimal responders were aged 20-40
155	years. Normal responders were older than suboptimal responders (the ratios of the
156	number of those aged 50-60 years were 57% vs. 0%, respectively), but no significant
157	difference was observed ( $P > 0.99$ ). In addition, the male/female ratio was higher in
158	suboptimal responders than in normal responders (74% vs. 15%), but no significant
159	difference was observed ( $P > 0.99$ ). All suboptimal responders were non-smokers and
160	non-obese, and none of them had a history of immunosuppressive drug use or having a
161	medical condition associated with immunodeficiency.
162	

# 163 SARS-CoV-2 anti-spike antibody levels

164	The median (IQR) SARS-CoV-2 anti-spike antibody titer was 2251.5 (1639.0–
165	3276.3) in the normal responders and 3721.0 (3255.0–4983.3) in the suboptimal
166	responders 1 week after receiving the second dose of BNT162b2 vaccine. This
167	difference was statistically significant ( $P$ =0.029) (Fig. 1A). For the total antibody level
168	1 week after the second vaccination, there was no significant difference in the median
169	antibody levels between those aged 50–60 years and those aged 20–40 years( $P$ =0.66).
170	The median (IQR) SARS-CoV-2 anti-spike antibody in normal responders was
171	2251.5 (1639.0–3276.3) and 779.3 (534.6–1024.3) measured 1 week and 5 months,
172	respectively, after receiving the second dose of BNT162b2 vaccine (Fig. 1B). In
173	suboptimal responders, the median (IQR) SARS-CoV-2 anti-spike antibody titters were

- 174 3721.0 (3255.0–4983.3) and 666.7 (578.9–880.6) measured 1 week and 5 months,
- 175 respectively, after receiving the second dose of BNT162b2 vaccine (Fig. 1C).
- 176 SARS-CoV-2 anti-spike antibody was produced by both suboptimal and normal
- 177 responders, but the level was lower at 5 months than at 1 week after the second dose of
- 178 vaccine (Fig. 1).

180 (A) SARS-CoV-2 anti-spike antibody responses over the whole study period from

- 181 before the first dose to 5 months after the second dose of vaccine.
- (B) SARS-CoV-2 anti-spike antibody titers in normal responders 1 week and 5 months
- 183 after receiving the second dose of the BNT162b2 vaccine. The antibody titers were
- 184 significantly lower at 5 months than at 1 week after the second dose (P < 0.001).
- 185 (C) SARS-CoV-2 anti-spike antibody titers in suboptimal responders 1 week and 5
- 186 months after receiving the second dose of the BNT162b2 vaccine. The antibody titers
- 187 decreased, but the decrease was not statistically significant (P=0.068).
- 188 The box plot comparisons were performed using the Mann–Whitney U test. *P*-values
- 189 <0.05 were considered statistically significant. Suboptimal responders had low-level
- 190 antibody responses to previous measles or mumps vaccines, and normal responders had
- 191 normal antibody responses to previous antiviral vaccines.
- 192 NaN; not a number
- 193

### 194 SARS-CoV-2 neutralizing antibody activity in participants with

195 suboptimal antibody responses to previous antiviral vaccines

196 SARS-CoV-2 neutralizing antibody titers were 1154.0 in L1 at 1 week after

197 receiving the second dose of BNT162b2 vaccine and 774.2, 638.3, and 654.6 in L2, L3,

and L4, respectively, at 1 month after receiving the second dose of BNT162b2 vaccine

- 199 (Fig. 2). In the 5 months after the second vaccination, SARS-CoV-2 neutralizing
- antibody titers were 105.5, 147.7, 485.2, and 894.4 in L1, L2, L3, and L4, respectively
- 201 (Fig. 2). All four suboptimal responders had a neutralizing antibody activity within the
- 202 protective range ( $\geq$ 50), from the 1 week to 1 month and 5 months after the second

- 203 vaccination (Fig. 2). The SARS-CoV-2 neutralizing antibody level in suboptimal
- responders was lower at 5 months after receiving the second dose of BNT162b2 vaccine
- than at 1 week to 1 month after receiving the second dose, but this difference was not
- statistically significant (*P*=0.38) (Fig. 2).

- 208 Data are presented as 50% inhibitory dilutions (ID<sub>50</sub>). The dashed line indicates the
- 209 cutoff for  $ID_{50}$  (17).
- 210

## 211 **Discussion**

- The BNT162b2 vaccine has been highly effective in preventing clinically
- significant COVID-19 (8-10). However, limited information is available about the
- effectiveness of the BNT162b2 vaccine in suboptimal responders to conventional
- 215 vaccines. In this study, suboptimal responders produced adequate SARS-CoV-2 anti-
- 216 spike antibodies and neutralizing antibodies.
- 217 Muik et al. (19) measured the neutralization efficacy of sera from 40 healthy
- 218 German individuals immunized with the BNT162b2 vaccine and a 50% inhibitory
- 219 dilution factor using pseudovirus according to the same method as was used in this
- study. The SARS-CoV-2 neutralizing activity of the suboptimal responders in this study
- 1 week to 1 month after receiving the second dose of BNT162b2 vaccine was
- comparable to that of the participants in the German study. All four suboptimal
- 223 responders developed protective levels of neutralizing antibodies. The SARS-CoV-2
- 224 neutralizing antibody activity value in the fifth month after the second dose of
- BNT162b2 vaccine did not show a significant decrease in activity compared with that 1
- week to 1 month after receiving the second dose of BNT162b2 vaccine. The SARS-

227	CoV-2 anti-spike antibody titer was lower at 5 months after the second dose of
228	BNT162b2 vaccine than at 1 week after the second dose, but the decrease was not
229	statistically significant in suboptimal responders. These results suggest that mRNA
230	vaccines can invoke a protective immune response even in suboptimal responders who
231	do not develop adequate antibody titers against viruses in response to conventional
232	vaccines against viral diseases such as mumps and measles.
233	Measles, rubella, chickenpox, and mumps vaccines are live attenuated vaccines
234	that weaken the toxicity of pathogenic microorganisms, and hepatitis B vaccines are
235	inactivated vaccines that cause pathogenic microorganisms to lose their ability to infect
236	(20). In previous studies, approximately 2–10% of healthy individuals do not produce
237	protective antibody levels in response to viral vaccines (21). The risk factors for low
238	response to these conventional viral vaccines include male sex, age of >40 years,
239	smoking habit, obesity, chronic diseases, and genetic factors. However, the factors
240	associated with a low antibody response to SARS-CoV-2 mRNA vaccines are not well
241	understood. Smokers, patients with cancer and hematological malignancies, and organ
242	transplant recipients have been reported to have a lower SARS-CoV-2 anti-spike
243	antibody response than individuals without these characteristics after receiving SARS-
244	CoV-2 vaccines (22-26). It is intriguing that the suboptimal responders in this study who
245	did not produce adequate antibodies against measles or mumps produced adequate
246	SARS-CoV-2 anti-spike antibodies after receiving the BNT162b2 vaccine. They were
247	healthy and did not have risk factors such as an organ transplant and
248	immunosuppression. One possible reason for this discrepancy is the different

249 mechanism of antibody production between conventional vaccines and SARS-CoV-2
250 mRNA vaccines.

251	The BNT162b2 vaccine is an mRNA vaccine that incorporates mRNA
252	encoding spike protein (antigen) on the surface of the SARS-CoV-2 into human cells.
253	The produced antigen directly functions as a template to induce the acquired immune
254	system (27). On the other hand, with live attenuated vaccines or inactivated vaccines, it
255	is necessary for recipients to process the vaccine and recognize it as an antigen. The
256	difference in the mechanism of action of vaccines could be a factor contributing to the
257	discrepancy in response to the BNT162b2 vaccine from the response to conventional
258	live attenuated vaccines among suboptimal responders. Such a hypothesis should be
259	tested in future studies. It is also unclear why suboptimal responders had higher
260	antibody titers than normal responders in the first week after the second dose of vaccine.
261	Of note, the SARS-CoV-2 anti-spike antibody level is known to peak and then
262	decrease within months after the second vaccination, which is a much shorter period
263	than that of antibodies against live attenuated vaccines (28,29). In order to achieve
264	adequate COVID-19 disease control, a third dose of SARS-CoV-2 mRNA vaccine is
265	needed, which is already being administered in many countries. In view of the results of
266	the present study, a third dose of the BNT162b2 vaccine is recommended for both
267	suboptimal and normal responders to conventional vaccines. (28)
268	This study has some limitations. The number of participants was limited, and
269	all participants were HCWs vaccinated at a single hospital. In addition, there were no
270	suboptimal responders to inactivated vaccines (such as hepatitis B) included in this

271	study. Multicente	r studies with	a larger samp	le size are i	needed to a	confirm th	e results of

- the present study. In addition, further immunological studies are necessary to clarify the
- 273 mechanism by which humoral immunity is acquired after mRNA vaccination in
- 274 suboptimal responders to conventional vaccines.
- 275 In conclusion, after two doses of the BNT162b2 vaccine, suboptimal
- 276 responders to conventional antiviral vaccines developed protective levels of SARS-
- 277 CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies. These results suggest that
- 278 vaccination with mRNA vaccine against SARS-CoV-2 should also be recommended to
- 279 suboptimal responders against conventional vaccines.
- 280

#### 281 Ethics consideration

- 282 We carried out a prospective cohort study of 50 HCWs. This study was
- 283 conducted with the approval of the Ethics Committee of Kyorin University School of
- 284 Medicine (Number R02-041), and was in accordance with the Declaration of Helsinki.
- 285 Informed consent was obtained from all study participants.

286

### 287 Acknowledgments

288 We thank the HCWs of the Department of Clinical Laboratory, Kyorin

289 University Hospital involved in the SARS-CoV-2 antibody monitoring for their valuable290 contribution.

291

### 292 **References**

- 293 1. Coronaviridae Study Group of the International Committee on Taxonomy of
- 294 Viruses, Baker SC, Baric RS, et al. The species severe acute respiratory
- 295 syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-
- 296 2. Nat Microbiol 5:536-544, 2020.
- 297 2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory
- 298 disease in China. Nature 579:265-269, 2020.
- 299 3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new
- 300 coronavirus of probable bat origin. Nature 579:270-273, 2020.
- 3014.Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with

302 pneumonia in China, 2019. N Engl J Med 382:727-733, 2020.

- 303 5. Song Z, Xu Y, Bao L, et al. From SARS to MERS, Thrusting coronaviruses into
  304 the spotlight. Viruses 11:59, 2019.
- 305 6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry
- 306depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease
- 307 inhibitor. Cell 181:271-280.e8, 2020.
- 308 7. Jiang S, Lu L, Liu Q, Xu W, Du L. Receptor-binding domains of spike proteins of
- 309 emerging or re-emerging viruses as targets for development of antiviral vaccines.
- 310 Emerg Microbes Infect 1:e13, 2012.
- 8. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA
- 312 BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases,
- 313 hospitalisations, and deaths following a nationwide vaccination campaign in
- 314 Israel: an observational study using national surveillance data. Lancet 397:1819-
- 315 1829, 2021.

316 9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162	nas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2
--	---

- 317 mRNA Covid-19 vaccine. N Engl J Med 383:2603-2615, 2020.
- 318 10. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a
- ationwide mass vaccination setting. N Engl J Med 384:1412-1423, 2021.
- 320 11. Regev-Yochay G, Amit S, Bergwerk M, et al. Decreased infectivity following
- BNT162b2 vaccination: a prospective cohort study in Israel. Lancet Reg Health
  Eur 7:100150, 2021.
- 323 12. Petter E, Mor O, Zuckerman N, et al. Initial real world evidence for lower viral
- load of individuals who have been vaccinated by BNT162b2. Preprint; 2021.
- 325 13. Pharmaceuticals and Medical Devices Agency. Special Approval for Emergency
- 326 on first COVID-19 vaccine in Japan [media release]. 2021. Available from:
- 327 pmda.go.jp. [Cited 2022 February 20] Available from:
- 328 https://www.pmda.go.jp/english/about-pmda/0003.pdf
- 329 14. Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M.
- 330 Seroprevalence survey on measles, mumps, rubella and varicella antibodies in
- healthcare workers in Japan: sex, age, occupational-related differences and
- 332 vaccine efficacy. Epidemiol Infect. Cambridge University Press 142:12-19, 2014.
- 333 15. Riester E, Findeisen P, Hegel JK, et al. Performance evaluation of the Roche
- Elecsys anti-SARS-CoV-2 S immunoassay. J Virol Methods 297:114271, 2021.
- Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a
  pseudotyped virus-based assay. Nat Protoc 15:3699-3715, 2020.
- 337 17. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-
- 338 CoV-2 in rhesus macaques. Nature 590:630-634, 2021.

- 339 18. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for
- 340 medical statistics. Bone Marrow Transplant 48:452-458, 2013.
- 341 19. Muik A, Wallisch AK, Sänger B, et al. Neutralization of SARS-CoV-2 lineage
- 342 B.1.1.7 Pseudovirus by BNT162b2 vaccine-elicited human sera. Science
- **343 371:1152-1153**, 2021.
- 20. Krammer F. SARS-CoV-2 vaccines in development. Nature 586:516-527, 2020.
- 345 21. Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine
- 346 vaccines: why and what to do? Hum Vaccin Immunother 12:239-243, 2016.
- 347 22. Shem-Tov N, Yerushalmi R, Danylesko I, et al. Immunogenicity and safety of the
- 348 BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation
  349 recipients. Br J Haematol 196:884-891, 2022.
- 350 23. Nomura Y, Sawahata M, Nakamura Y, et al. Age and smoking predict antibody
- 351 titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine.
- 352 Vaccines (Basel) 9:1042, 2021.
- 353 24. Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is
- 354 significantly less effective in patients with hematologic malignancies. Am J
  355 Hematol 96:1195-1203, 2021.
- 356 25. Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one
  357 versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer:
  358 interim analysis of a prospective observational study. Lancet Oncol 22:765-778,
  359 2021.
- 360 26. Shroff RT, Chalasani P, Wei R, et al. Immune responses to two and three doses of
  361 the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med 27:2002-
- **362** 2011, 2021.

- 363 27. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-
- 364 SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug
- **365** Resist 14:3459-3476, 2021.
- 366 28. Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and
- 367 risk of SARS-CoV-2 infection: test negative design study. BMJ 375 :e067873,
- 368 2021.
- 369 29. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to
- BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 385:e84-e84, 2021.

## 372 Figure legends

- 373 Fig 1. SARS-CoV-2 anti-spike antibody responses in suboptimal/normal
- 374 responders before and after vaccination with the BNT162b2 vaccine
- 375
- 376 Fig 2. SARS-CoV-2 neutralizing antibody activity responses after the second dose
- 377 of BNT162b2 vaccine in suboptimal responders

















